Patents Represented by Attorney Jayadeep R. Deshmukh, Esq.

Find this attorney in the Justia Lawyer Directory

  • 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    Patent number: 7560479
    Abstract: This invention relates to derivatives of 3,6-disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: July 14, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Bruhaspathy Miriyala, Arundutt Viswanatham Silamkoti, Jang Bahadar Gupta
  • Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    Patent number: 7517905
    Abstract: This invention relates to the derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: April 14, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Bruhaspathy Miriyala, Sudershan Kumar Arora, Jang Bahadur Gupta
  • Flavaxate derivatives as muscarinic receptor antagonists
    Patent number: 7501443
    Abstract: This invention generally relates to the derivatives of 3.6-disubstituted azabicyclo [3.1.0] hexanes of the following formula [IA]. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the :h1ethods for treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: March 10, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Sanjay Kumar Srivastava, Jang Bahadur Gupta
  • 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
    Patent number: 7488748
    Abstract: This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: February 10, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Arundutt V. Silamkoti, Naresh Kumar, Jang Bahadur Gupta
  • Amorphous form of esomeprazole salts
    Patent number: 7482463
    Abstract: The invention relates to an amorphous form of the salts of the (-) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amorphous esomeprazole salts.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: January 27, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Mahavir Singh Khanna, Bakthavathsalan Vijayaraghavan, Mohan Prasad, Yatendra Kumar
  • 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
    Patent number: 7465751
    Abstract: This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: December 16, 2008
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Jang Bahadur Gupta, Pakala Kumara Savithru Sarma
  • Process for the preparation of imipenem
    Patent number: 7462712
    Abstract: The present invention relates to an improved process for the preparation of imipenem comprising reacting a bicyclo ketone precursor of the Formula II, wherein R is a protecting group, with a phosphorohalidate in the presence of a base and a catalytic amount of dialkylaminopyridine.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: December 9, 2008
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Neera Tewari, Bishwa Prakash Rai
  • 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
    Patent number: 7410993
    Abstract: This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0] hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: August 12, 2008
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Arundutt V. Silamkoti, Miriyala Bruhaspathy, Jang Bahadur Gupta
  • 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
    Patent number: 7399779
    Abstract: This invention generally relates to the derivatives of novel 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: July 15, 2008
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Arundutt V. Silamkoti, Jang Bahadur Gupta
  • Process for the preparation of crystalline imipenem
    Patent number: 7332600
    Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity, which comprises dissolving crude imipenerm in warm water to which some base has been added to obtain a solution, subjecting the resultant solution to activated carbon treatment, and adding an organic solvent to precipitate imipienem monohydrate as a crystalline product.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: February 19, 2008
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Bishwa Prakash Rai, Neera Tewari, Yatendra Kumar
  • 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
    Patent number: 7265147
    Abstract: This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: September 4, 2007
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Arundutt V. Silamkoti, Kirandeep Kaur, Jang Bahadur Gupta
  • Process for the isolation of crystalline imipenem
    Patent number: 7241885
    Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity comprising the steps of treating an aqueous solution containing imipenem with an organic solvent, wherein the imipenem is not lyophilized; and isolating the pure crystalline imipenem monohydrate from the reaction mixture thereof.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: July 10, 2007
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Neera Tewari, Ram Chander Aryan, Bishwa Prakash Rai
  • 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
    Patent number: 7232835
    Abstract: This invention relates to derivatives of 3,6-disubstituted azabicyclo compounds. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: June 19, 2007
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Arundutt Viswanatham Silamkoti, Bruhaspathy Miriyala, Sudershan Kumar Arora, Boju Srinivasulu, Bireshwar Mukherjee, Jang Bahadur Gupta
  • Process for the preparation of repaglinide
    Patent number: 7148355
    Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of repaglinide.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: December 12, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Purna Chandra Ray, Jayachandra Suresh Babu, Mohammad Salman, Naresh Kumar
  • Process for the preparation of acitretin
    Patent number: 7129365
    Abstract: The present invention relates to a cost effective and industrially useful process for the preparation of substantially pure acitretin. More specifically, the present invention relates to the preparation of acitretin of high purity and yield.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: October 31, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Mohan Prasad, Kaptan Singh, Pankaj Sharma
  • Processes for the preparation of oral dosage formulations of modafinil
    Patent number: 7115281
    Abstract: The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%–25% by weight of modafinil particles having diameters greater than 220 ?m and about 75%–93% by weight of modafinil particles having diameters less than 220 ?m.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: October 3, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Romi Barat Singh, Pannanchukunnath Manoj Kumar, Vishnubhotla Nagaprasad, Sunilendu Bhushan Roy, Rajiv Malik
  • Tamsulosin derivative
    Patent number: 7084301
    Abstract: The optically active compound, R (?)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide in good optical purity, a metabolite of the ?1-adrenergic blocking agent tamsulosin, and methods for the preparation thereof. Pharmaceutical compositions including the optically active compound and methods of treatment comprising administration of an effective ?1-adrenergic antagonistic amount of such compositions to mammals.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: August 1, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Ram Chander Aryan, Radhakrishnan Gowri Shankar, Kumar Hari Bhushan, Anita Chugh
  • HMG CoA-reductase inhibitors
    Patent number: 7078430
    Abstract: The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I and their corresponding lactones.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: July 18, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Ram Chander Aryan, Jitendra Sattigeri, Mohammad Salman, Gowri Shankar, Kumar Hari Bhushan, Bhargav R. Panyda, Ramnik Sharma
  • Process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (imipenem monohydrate)
    Patent number: 7078534
    Abstract: The present invention relates to a cost effective and commercially viable process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (Imipenem monohydrate) of Formula I.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: July 18, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Neera Tewari, Ran Chander Aryan, Bishwa Prakash Rai, Seema Ahuja
  • Process for the isolation of lovastatin
    Patent number: 7052886
    Abstract: The process for the preparation and isolation of the hypolipaemic active substance lovastatin in substantially pure form having a purity of at least 95% which comprises lactonizing the mevinolinic acid to lovastatin in a totally aqueous medium.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: May 30, 2006
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Parveen Kumar, Srinivasan Raman, Pardeep Narula